We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$1.74B
AUM Growth
+$18.9M
Cap. Flow
-$61.5M
Cap. Flow %
-3.53%
Top 10 Hldgs %
23.9%
Holding
276
New
11
Increased
44
Reduced
193
Closed
16

Top Buys

Rank Stock Value
1
OABI icon
OmniAb
OABI
+$13M
2
DOCS icon
Doximity
DOCS
+$10.2M
3
LOB icon
Live Oak Bancshares
LOB
+$7.32M
4
RXO icon
RXO
RXO
+$7.31M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.78M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$24.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$12.4M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$12.3M
4
XPO icon
XPO
XPO
+$7.84M
5
RXT icon
Rackspace Technology
RXT
+$5.42M

Sector Composition

Rank Sector Weight
1 Technology 27.01%
2 Healthcare 26.13%
3 Industrials 15.45%
4 Consumer Discretionary 11.41%
5 Communication Services 6.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$16.6B
$17.8M 1.02%
149,367
-3,552
-2% -$416K
ASND icon
27
Ascendis Pharma A/S
ASND
$16.8B
$17.8M 1.02%
145,739
+9,294
+7% +$1.08M
IAA
28
DELISTED
IAA, Inc. Common Stock
IAA
$17.7M 1.01%
441,862
+985
+0.2% +$37.2K
SMTC icon
29
Semtech
SMTC
$13B
$17.1M 0.98%
595,028
+22,147
+4% +$628K
FC icon
30
Franklin Covey
FC
$246M
$16.9M 0.97%
362,370
+14,490
+4% +$707K
PCRX icon
31
Pacira BioSciences
PCRX
$997M
$16.9M 0.97%
437,285
+29,407
+7% +$1.43M
MMS icon
32
Maximus
MMS
$3.1B
$16.4M 0.94%
223,792
-37,255
-14% -$2.4M
OZK icon
33
Bank OZK
OZK
$5.61B
$16.4M 0.94%
408,936
-132
-0% -$5.67K
RVNC
34
DELISTED
Revance Therapeutics, Inc.
RVNC
$16.2M 0.93%
875,496
-21,258
-2% -$486K
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$5.03B
$15.2M 0.87%
957,688
+433,818
+83% +$6.78M
BBBY
36
Bed Bath & Beyond
BBBY
$442M
$15.1M 0.87%
856,965
+235,147
+38% +$5.06M
POOL icon
37
Pool Corp
POOL
$7.5B
$14.8M 0.85%
48,793
-58
-0.1% -$18.4K
CEVA icon
38
CEVA Inc
CEVA
$1.08B
$12.9M 0.74%
504,583
-7,799
-2% -$210K
QLYS icon
39
Qualys
QLYS
$6.35B
$12.5M 0.72%
111,099
-110
-0.1% -$13.7K
PGTI
40
DELISTED
PGT, Inc.
PGTI
$12.5M 0.71%
693,370
-142,989
-17% -$2.91M
LMAT icon
41
LeMaitre Vascular
LMAT
$1.86B
$11.7M 0.67%
255,302
-7,062
-3% -$331K
IOVA icon
42
Iovance Biotherapeutics
IOVA
$2.87B
$11.6M 0.67%
1,822,080
+388,024
+27% +$3.03M
UTMD icon
43
Utah Medical Products
UTMD
$225M
$11.5M 0.66%
114,366
-3,172
-3% -$290K
XPO icon
44
XPO
XPO
$23.7B
$11.4M 0.65%
342,776
-232,652
-40% -$7.84M
PRGS icon
45
Progress Software
PRGS
$1.76B
$11.4M 0.65%
226,087
-5,427
-2% -$271K
ALBO
46
DELISTED
Albireo Pharma Inc
ALBO
$11.1M 0.64%
513,525
+9,387
+2% +$198K
ARLO icon
47
Arlo Technologies
ARLO
$1.65B
$11M 0.63%
3,132,519
+858,203
+38% +$3.53M
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$5.93B
$10.4M 0.6%
697,162
-52,771
-7% -$768K
CCSI icon
49
Consensus Cloud Solutions
CCSI
$647M
$10.1M 0.58%
188,171
-1,259
-0.7% -$68.6K
ATEN icon
50
A10 Networks
ATEN
$1.95B
$9.83M 0.56%
591,078
-21,356
-3% -$366K
1
2
3 4 5

Similar funds

WFMPM
Woodley Farra Manion Portfolio Management Indianapolis, Indiana $2.05B AUM 14.54% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
HBT
Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return
IL
Investure LLC Charlottesville, Virginia $2.04B AUM 15.91% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
SW
SoFi Wealth San Francisco, California $2.08B AUM 18.22% 1-Year Est. Return
SAM
Southeastern Asset Management Memphis, Tennessee $2.03B AUM 7.06% 1-Year Est. Return

Rice Hall James & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Rice Hall James & Associates held 276 positions worth $1.74B, up 1.1% from $1.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rice Hall James & Associates withdrew a net $61.5M in Q4 2022, closing 16 positions and reducing 193 holdings. Its most notable exit was Aerie Pharmaceuticals, an estimated $24.3M position sold in full.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in OmniAb worth $8.94M.

  • Rice Hall James & Associates's largest Q4 2022 buy was OmniAb: 2,483,766 shares worth $8.94M.
  • Rice Hall James & Associates added most to Doximity in Q4 2022, an estimated $10.2M increase.
  • Rice Hall James & Associates's biggest Q4 2022 reduction was Ligand Pharmaceuticals, cutting an estimated $12.3M.
  • Rice Hall James & Associates fully exited Aerie Pharmaceuticals in Q4 2022, selling an estimated $24.3M.
  • Rice Hall James & Associates's ten largest holdings make up 24% of its $1.74B portfolio in Q4 2022.
  • Rice Hall James & Associates opened 11 new positions and closed 16 in Q4 2022.
  • Rice Hall James & Associates's portfolio value rose 1.1% quarter-over-quarter to $1.74B.

Based on Rice Hall James & Associates's 13F filing for Q4 2022, filed 27 Jan 2023.